FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2982712529> ?p ?o ?g. }

• W2982712529 endingPage "3260" @default.
• W2982712529 startingPage "3260" @default.
• W2982712529 abstract "Background Transplantation-associated thrombotic microangiopathy (TA-TMA) is a significant complication after allogeneic hematopoietic stem cell transplantation (allo-HSCT) and may affect 20% of recipients on average. A few groups have proposed risk or prognostic factors for TA-TMA, including a recent prospective study in a cohort that included both children and young adults (Jodele et al. Blood 2014), yet there has been no reproduced or validated data for consensus. Furthermore, with rapid advances in transplantation technology such as an increased variety of donors, conditioning regimens, and graft-versus-host disease (GVHD) prophylaxis, currently used diagnostic criteria and risk factors for TA-TMA must be re-evaluated using recent large cohorts. Patients and method The purpose of this study is to investigate risk and prognostic factors for TA-TMA in adult patients with acute myeloid leukemia (AML). TA-TMA was primarily diagnosed with previously published diagnostic criteria proposed by our group (Cho et al. Transplantation 2010). Then, we analyzed TA-TMA incidence, risk, and prognostic factors in two independent cohorts for training (n = 382, 2012-2015, retrospective) and validation (n = 231, 2016-2017, prospective). In particular, predictive factors for TA-TMA in a prospective cohort, including children and young adults as recently suggested by Jodele et al., were evaluated in our adult AML patients. Results In the entire cohort (n = 613), the median TA-TMA onset was 66 (range, 5-511) days from allo-HSCT. Among TA-TMA patients, 33.6% and 32.6% of them suffered from proteinuria and AKI, respectively. Also, 33.2% suffered from preceding or concurrent hemorrhagic cystitis (any grade), and 12.7% suffered from VOD/SOS at the time of TA-TMA diagnosis. Regarding the treatment of TA-TMA, 87.3% of patients discontinued or reduced the calcineurin inhibitor with supportive care, while 12.7%, 5.6%, and 4.2% were treated with total plasma exchange, t-PA, and defibrotide addition to calcineurin inhibitor dose modification, respectively. Thirty percent of patients achieved complete remission, and TA-TMA was related to poor three-year OS. There were no significant clinical characteristic differences between the training and validation cohorts with the exception of more haploidentical allo-HSCT in the validation cohort (training vs. validation; 26.7% vs. 36.4%, p = 0.012), and the cumulative incidence of TA-TMA was significantly (p < 0.001) higher among the validation cohort (18.8%) than the training cohort (8.9%). For the risk factors of TA-TMA, univariate and multivariate analyses revealed that LDH > 1.5 x upper normal limit (training p = 0.042 and validation p = 0.0042), proteinuria ≥30 mg/dL (training p = 0.0019 and validation p = 0.0012), and ≥Grade I hemorrhagic cystitis (training p = 0.0460 and validation p = 0.0049) were significantly associated with an increased risk of TA-TMA in both the training and validation cohorts. Among patients with TA-TMA, concurrent hemorrhagic cystitis upon diagnosis of TA-TMA was a significant factor for inferior overall survival in the entire cohort (32.3% vs. 5.9%, p = 0.031). Conclusions This study validates the feasibility of diagnostic criteria for TA-TMA proposed by our group with a recent large cohort consisting of training and validation cohorts and points out the role of preceding hemorrhagic cystitis as a risk and prognostic factor for TA-TMA in AML. Of note, proteinuria and elevated LDH prior to the appearance of MAHA proposed by Jodele et al. with a younger population were proven to be useful for predicting the occurrence of TA-TMA among adult populations with AML. Disclosures Kim: Celgene: Consultancy, Honoraria; Astellas: Consultancy, Honoraria; Hanmi: Consultancy, Honoraria; AGP: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees; SL VaxiGen: Consultancy, Honoraria; Novartis: Consultancy; Amgen: Honoraria; Chugai: Honoraria; Yuhan: Honoraria; Sanofi-Genzyme: Honoraria, Research Funding; Novartis: Honoraria, Membership on an entity's Board of Directors or advisory committees; Handok: Honoraria; Janssen: Honoraria; Daiichi Sankyo: Honoraria, Membership on an entity's Board of Directors or advisory committees; Otsuka: Honoraria; BL & H: Research Funding. Kim:BMS: Research Funding; Pfizer: Research Funding; Takeda: Research Funding; Il-Yang co.: Research Funding; Novartis: Research Funding. Lee:Achillion: Research Funding; Alexion: Consultancy, Honoraria, Research Funding." @default.
• W2982712529 created "2019-11-22" @default.
• W2982712529 creator A5014324967 @default.
• W2982712529 creator A5021692797 @default.
• W2982712529 creator A5031805513 @default.
• W2982712529 creator A5033356298 @default.
• W2982712529 creator A5034751203 @default.
• W2982712529 creator A5036020306 @default.
• W2982712529 creator A5044372572 @default.
• W2982712529 creator A5050292329 @default.
• W2982712529 creator A5050627824 @default.
• W2982712529 creator A5055206475 @default.
• W2982712529 creator A5059291757 @default.
• W2982712529 creator A5067818349 @default.
• W2982712529 creator A5074128691 @default.
• W2982712529 creator A5080353333 @default.
• W2982712529 creator A5081217020 @default.
• W2982712529 creator A5084426605 @default.
• W2982712529 creator A5086415059 @default.
• W2982712529 date "2019-11-13" @default.
• W2982712529 modified "2023-10-09" @default.
• W2982712529 title "Validation of Recently Proposed Risk and Prognostic Factors for Thrombotic Microangiopathy after Allogeneic Hematopoietic Stem Cell Transplantation in Acute Myeloid Leukemia" @default.
• W2982712529 doi "https://doi.org/10.1182/blood-2019-124275" @default.
• W2982712529 hasPublicationYear "2019" @default.
• W2982712529 type Work @default.
• W2982712529 sameAs 2982712529 @default.
• W2982712529 citedByCount "0" @default.
• W2982712529 crossrefType "journal-article" @default.
• W2982712529 hasAuthorship W2982712529A5014324967 @default.
• W2982712529 hasAuthorship W2982712529A5021692797 @default.
• W2982712529 hasAuthorship W2982712529A5031805513 @default.
• W2982712529 hasAuthorship W2982712529A5033356298 @default.
• W2982712529 hasAuthorship W2982712529A5034751203 @default.
• W2982712529 hasAuthorship W2982712529A5036020306 @default.
• W2982712529 hasAuthorship W2982712529A5044372572 @default.
• W2982712529 hasAuthorship W2982712529A5050292329 @default.
• W2982712529 hasAuthorship W2982712529A5050627824 @default.
• W2982712529 hasAuthorship W2982712529A5055206475 @default.
• W2982712529 hasAuthorship W2982712529A5059291757 @default.
• W2982712529 hasAuthorship W2982712529A5067818349 @default.
• W2982712529 hasAuthorship W2982712529A5074128691 @default.
• W2982712529 hasAuthorship W2982712529A5080353333 @default.
• W2982712529 hasAuthorship W2982712529A5081217020 @default.
• W2982712529 hasAuthorship W2982712529A5084426605 @default.
• W2982712529 hasAuthorship W2982712529A5086415059 @default.
• W2982712529 hasConcept C120665830 @default.
• W2982712529 hasConcept C121332964 @default.
• W2982712529 hasConcept C126322002 @default.
• W2982712529 hasConcept C141071460 @default.
• W2982712529 hasConcept C143998085 @default.
• W2982712529 hasConcept C188816634 @default.
• W2982712529 hasConcept C2777408962 @default.
• W2982712529 hasConcept C2777878052 @default.
• W2982712529 hasConcept C2778729363 @default.
• W2982712529 hasConcept C2779134260 @default.
• W2982712529 hasConcept C2911091166 @default.
• W2982712529 hasConcept C61511704 @default.
• W2982712529 hasConcept C71924100 @default.
• W2982712529 hasConcept C72563966 @default.
• W2982712529 hasConcept C88879693 @default.
• W2982712529 hasConceptScore W2982712529C120665830 @default.
• W2982712529 hasConceptScore W2982712529C121332964 @default.
• W2982712529 hasConceptScore W2982712529C126322002 @default.
• W2982712529 hasConceptScore W2982712529C141071460 @default.
• W2982712529 hasConceptScore W2982712529C143998085 @default.
• W2982712529 hasConceptScore W2982712529C188816634 @default.
• W2982712529 hasConceptScore W2982712529C2777408962 @default.
• W2982712529 hasConceptScore W2982712529C2777878052 @default.
• W2982712529 hasConceptScore W2982712529C2778729363 @default.
• W2982712529 hasConceptScore W2982712529C2779134260 @default.
• W2982712529 hasConceptScore W2982712529C2911091166 @default.
• W2982712529 hasConceptScore W2982712529C61511704 @default.
• W2982712529 hasConceptScore W2982712529C71924100 @default.
• W2982712529 hasConceptScore W2982712529C72563966 @default.
• W2982712529 hasConceptScore W2982712529C88879693 @default.
• W2982712529 hasIssue "Supplement_1" @default.
• W2982712529 hasLocation W29827125291 @default.
• W2982712529 hasOpenAccess W2982712529 @default.
• W2982712529 hasPrimaryLocation W29827125291 @default.
• W2982712529 hasRelatedWork W1473782864 @default.
• W2982712529 hasRelatedWork W2004368639 @default.
• W2982712529 hasRelatedWork W2147261346 @default.
• W2982712529 hasRelatedWork W2360260519 @default.
• W2982712529 hasRelatedWork W2516907989 @default.
• W2982712529 hasRelatedWork W2559978871 @default.
• W2982712529 hasRelatedWork W2949644692 @default.
• W2982712529 hasRelatedWork W2981721666 @default.
• W2982712529 hasRelatedWork W2993129723 @default.
• W2982712529 hasRelatedWork W4307885801 @default.
• W2982712529 hasVolume "134" @default.
• W2982712529 isParatext "false" @default.
• W2982712529 isRetracted "false" @default.
• W2982712529 magId "2982712529" @default.
• W2982712529 workType "article" @default.